Eli Kids EFC13738 Summary: Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients
Eli Kids EFC13738
read more
sEARCH RESULTS
FollowMe
FollowMeClick the button below to view the followME Fabry Pathfinders webiste
GTX-102
GTX-102Summary: A phase 1/2 open-label, multiple-dose, dose-escalating clinical trial of the safety and tolerability of GTX-102 in pediatric patients with Angelman Syndrome (AS)
ST-920-201
ST-920-201Dose-ranging study of ST-290, an AAV2/6 Human Alpha Galactosidase - a gene therapy in subjects with Fabry disease DOSE-RANGING STUDY OF ST-920, AN AAV2/6 HUMAN ALPHA GALACTOSIDASE A GENE THERAPY IN SUBJECTS WITH FABRY DISEASE
CMVIBE TRIAL
CMVIBE TRIAL Summary: A phase 1/2A open-label dose-ranging and observer-blind placebo-controlled, safety and immunogenicity study of mRNA-1647 Cytomegalovirus vaccine in female and male participants 9 to 15 years of age and participants 16 to 25 years of age.